Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERLEN frontline tafasitamab + lenalidomide + rituximab study in patients aged 80 years or older with diffuse large B-cell lymphoma
2023-507286-25-00Phase 2Authorised
- Sponsor
- LYSARC
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab, lenalidomide and rituximab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and follicular lymphoma (FL), sponsored by LYSARC. Primary endpoint: Overall response rate. Planned start Jan 2024; status: authorised.
02
Drugs
tafasitamablenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-507286-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507286-25-00.